In animal models of allergic asthma, idiopathic pulmonary fibrosis (IPF), and bronchiolitis obliterans syndrome (BOS), CCL2 expression and protein production are increased and the disease process is attenuated by CCL2 immuno-neutralization. Here, CCL2 is linked to bronchiolitis obliterans syndrome.